Avutometinib is under clinical development by Verastem and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Avutometinib’s likelihood of approval (LoA) and phase transition for Colorectal Cancer took place on 09 Sep 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

In addition, the same event on 09 Sep 2022 decreased Avutometinib’s Phase Transition Success Rate (PTSR) for Metastatic Pancreatic Cancer, decreased PTSR for Multiple Myeloma (Kahler Disease), and decreased LoA and PTSR for Solid Tumor.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Avutometinib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Avutometinib overview

CKI-27 (RG-7304, RO5126766) is under development for the treatment of solid tumors including low-grade serous ovarian cancer (LGSOC) , peritoneal cancer, metastatic uveal melanoma, metastatic pancreatic cancer, non-small cell lung cancer, multiple myeloma, endometrial cancer, prostate cancer, cervical cancer, HER2 negative breast cancer and colorectal cancer. It is administered orally as a capsule. It is a new molecular entity (NME) with a structure based on a coumarin skeleton. The drug candidate acts by targeting B-Raf kinase, C-Raf kinase, mitogen activated protein kinase kinase 1 (MEK-1 or MAP2K1). It was also under development for melanoma, pancreatic cancer and solid tumors in Japan.

Verastem overview

Verastem is a biopharmaceutical company. It carries out the discovery, development, and commercialization of novel small molecule drugs to treat cancer. The company’s most advanced product candidates include VS-6766, defactinib (VS-6063). Verastem products VS-6766 and defactinib (VS-6063), are being investigated in both preclinical and clinical studies for the treatment of various solid tumors, including, low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer, uveal melanoma, and endometrial cancer. The pipeline products focused on RAF/MEK inhibition and FAK inhibition. Its service include investigator sponsored trial (IST)program. The company operates in Germany and the US. Verastem is headquartered in Needham, Massachusetts, the US.

Quick View Avutometinib LOA Data

Report Segments
  • Innovator
Drug Name
  • Avutometinib
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: Verastem
  • Originator: Chugai Pharmaceutical
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.